[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy]

Gan To Kagaku Ryoho. 2006 Sep;33(9):1257-60.
[Article in Japanese]

Abstract

The clinical efficacy and safety of weekly paclitaxel therapy were studied retrospectively in 17 patients with advanced and recurrent gastric cancer who had previously been treated with TS-1 therapy. The overall response rate was 0%, but MST was 495 days. The adverse effects observed were grade 3 leukopenia in 2 patients (11.8%) and grade 1 and 2 alopecia in 13 patients (76.5%). However, weekly paclitaxel therapy was performed for all outpatients. Weekly paclitaxel therapy could be useful and safe as second-line chemotherapy.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Alopecia / chemically induced
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Oxonic Acid / administration & dosage
  • Paclitaxel / administration & dosage*
  • Paclitaxel / adverse effects
  • Quality of Life
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / mortality
  • Survival Rate
  • Tegafur / administration & dosage

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Phytogenic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Paclitaxel